BioSpace News Archive

Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and nine months ended December 31, 2023.

Genomics plc (Genomics), a healthcare company aiming to transform health through the power of genomics, today announced that the results of its HEART study (Healthcare Evaluation of Absolute Risk Testing) have been published in the European Journal of Preventive Cardiology.

Attendees at this year’s American College of Foot & Ankle Surgeons Annual Conference in Tampa, Florida will be the first to see restor3d’s newest Foot & Ankle offerings.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), one of the leading Canadian biotechnology companies

SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced that on January 8th 2024, the last patient was treated with its Renal Artery Denervation TIVUS™ technology, as part of its FDA IDE-approved pilot study to treat hypertension (The REDUCED-1 Study).

Medline has announced the signing of a five-year primary supplier vendor agreement with St. Luke’s, headquartered in Duluth, Minnesota.

Galapagos NV announced the successful completion of the transaction to transfer its Jyseleca® business to Alfasigma S.p.A.

Spero Therapeutics, Inc. announced that on January 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

NANOBIOTIX announced that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

Accuray Incorporated reported financial results for the second quarter and six-months ended December 31, 2023.